Literature DB >> 22321194

β-Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR-α, PPAR-γ and TRPV1, but not CB₁ or CB₂ receptors.

Cristina Benito1, Rosa María Tolón, Ana Isabel Castillo, Lourdes Ruiz-Valdepeñas, José Antonio Martínez-Orgado, Francisco Javier Fernández-Sánchez, Carmen Vázquez, Benjamin F Cravatt, Julián Romero.   

Abstract

BACKGROUND AND
PURPOSE: The endocannabinoid system may regulate glial cell functions and their responses to pathological stimuli, specifically, Alzheimer's disease. One experimental approach is the enhancement of endocannabinoid tone by blocking the activity of degradative enzymes, such as fatty acid amide hydrolase (FAAH). EXPERIMENTAL APPROACH: We examined the role of FAAH in the response of astrocytes to the pathologic form of β-amyloid (Aβ). Astrocytes from wild-type mice (WT) and from mice lacking FAAH (FAAH-KO) were incubated with Aβ for 8, 24 and 48 h, and their inflammatory responses were quantified by elisa, western-blotting and real-time quantitative-PCR. KEY
RESULTS: FAAH-KO astrocytes were significantly more responsive to Aβ than WT astrocytes, as shown by the higher production of pro-inflammatory cytokines. Expression of COX-2, inducible NOS and TNF-α was also increased in Aβ-exposed KO astrocytes compared with that in WTs. These effects were accompanied by a differential pattern of activation of signalling cascades involved in mediating inflammatory responses, such as ERK1/2, p38MAPK and NFκB. PPAR-α and PPAR-γ as well as transient receptor potential vanilloid-1 (TRPV1), but not cannabinoid CB₁ or CB₂ receptors, mediate some of the differential changes observed in Aβ-exposed FAAH-KO astrocytes. The pharmacological blockade of FAAH did not render astrocytes more sensitive to Aβ. In contrast, exogenous addition of several acylethanolamides (anandamide, palmitoylethanolamide and oleoylethanolamide) induced an antiinflammatory response.
CONCLUSIONS: The genetic deletion of FAAH in astrocytes exacerbated their inflammatory phenotype against Aβ in a process involving PPAR-α, PPAR-γ and TRPV1 receptors.
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22321194      PMCID: PMC3417461          DOI: 10.1111/j.1476-5381.2012.01889.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  67 in total

Review 1.  Key signaling pathways regulate the biological activities and accumulation of amyloid-beta.

Authors:  T Wyss-Coray; L McConlogue; M Kindy; A M Schmidt; S Du Yan; D M Stern
Journal:  Neurobiol Aging       Date:  2001 Nov-Dec       Impact factor: 4.673

2.  Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study.

Authors:  J Romero; C J Hillard; M Calero; A Rábano
Journal:  Brain Res Mol Brain Res       Date:  2002-04-30

3.  Molecular and cellular mediators of Alzheimer's disease inflammation.

Authors:  Ron Strohmeyer; Joseph Rogers
Journal:  J Alzheimers Dis       Date:  2001-02       Impact factor: 4.472

4.  Guide to Receptors and Channels (GRAC), 5th edition.

Authors:  Stephen P H Alexander; Alistair Mathie; John A Peters
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

5.  Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity.

Authors:  David A Karanian; Queenie B Brown; Alexandros Makriyannis; Therese A Kosten; Ben A Bahr
Journal:  J Neurosci       Date:  2005-08-24       Impact factor: 6.167

6.  Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia.

Authors:  Jihong Xu; Paul D Drew
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

Review 7.  Cannabinoid signaling in glial cells.

Authors:  Nephi Stella
Journal:  Glia       Date:  2004-12       Impact factor: 7.452

Review 8.  The role of inflammation in Alzheimer's disease.

Authors:  Ehab E Tuppo; Hugo R Arias
Journal:  Int J Biochem Cell Biol       Date:  2005-02       Impact factor: 5.085

9.  Capsaicin-induced apoptosis of glioma cells is mediated by TRPV1 vanilloid receptor and requires p38 MAPK activation.

Authors:  C Amantini; M Mosca; M Nabissi; R Lucciarini; S Caprodossi; A Arcella; F Giangaspero; G Santoni
Journal:  J Neurochem       Date:  2007-04-17       Impact factor: 5.372

10.  Cannabinoids inhibit sodium-dependent, high-affinity excitatory amino acid transport in cultured rat cortical astrocytes.

Authors:  Amruthesh C Shivachar
Journal:  Biochem Pharmacol       Date:  2007-03-24       Impact factor: 5.858

View more
  29 in total

1.  Dual role of PPAR-γ in induction and expression of behavioral sensitization to cannabinoid receptor agonist WIN55,212-2.

Authors:  Leili Enayatfard; Farzaneh Rostami; Sanaz Nasoohi; Shahrbanoo Oryan; Abolhassan Ahmadiani; Leila Dargahi
Journal:  Neuromolecular Med       Date:  2013-06-21       Impact factor: 3.843

2.  2-Pentadecyl-2-Oxazoline Reduces Neuroinflammatory Environment in the MPTP Model of Parkinson Disease.

Authors:  Marika Cordaro; Rosalba Siracusa; Rosalia Crupi; Daniela Impellizzeri; Alessio Filippo Peritore; Ramona D'Amico; Enrico Gugliandolo; Rosanna Di Paola; Salvatore Cuzzocrea
Journal:  Mol Neurobiol       Date:  2018-04-14       Impact factor: 5.590

Review 3.  New approaches and challenges to targeting the endocannabinoid system.

Authors:  Vincenzo Di Marzo
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

4.  Medial prefrontal cortex TRPV1 and CB1 receptors modulate cardiac baroreflex activity by regulating the NMDA receptor/nitric oxide pathway.

Authors:  Davi C Lagatta; Luciana B Kuntze; Nilson C Ferreira-Junior; Leonardo B M Resstel
Journal:  Pflugers Arch       Date:  2018-05-29       Impact factor: 3.657

Review 5.  Metabolic and Inflammatory Adaptation of Reactive Astrocytes: Role of PPARs.

Authors:  José Iglesias; Ludis Morales; George E Barreto
Journal:  Mol Neurobiol       Date:  2016-03-17       Impact factor: 5.590

6.  Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models.

Authors:  Paula Morales; Patricia H Reggio
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation.

Authors:  Newman Osafo; Oduro K Yeboah; Aaron O Antwi
Journal:  Mol Biol Rep       Date:  2021-04-28       Impact factor: 2.316

Review 8.  Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.

Authors:  Javier Fernández-Ruiz; María A Moro; José Martínez-Orgado
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

9.  Clinical studies and anti-inflammatory mechanisms of treatments.

Authors:  Jacqueline A French; Matthias Koepp; Yvonne Naegelin; Federico Vigevano; Stéphane Auvin; Jong M Rho; Evan Rosenberg; Orrin Devinsky; Peder S Olofsson; Marc A Dichter
Journal:  Epilepsia       Date:  2017-07       Impact factor: 5.864

Review 10.  Cannabinoids and the expanded endocannabinoid system in neurological disorders.

Authors:  Luigia Cristino; Tiziana Bisogno; Vincenzo Di Marzo
Journal:  Nat Rev Neurol       Date:  2019-12-12       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.